Search

Bio-Techne Corp

Closed

SectorHealthcare

72.4 0.28

Overview

Share price change

24h

Current

Min

72.03

Max

72.25

Key metrics

By Trading Economics

Income

13M

51M

Sales

16M

311M

P/E

Sector Avg

103.029

57.002

EPS

0.51

Dividend yield

0.44

Profit margin

16.392

Employees

3,100

EBITDA

21M

99M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-1.86% downside

Dividends

By Acuity

Dividend yield

Sector Avg

0.44%

2.22%

Next Earnings

4 lis 2026

Next Dividend date

28 sie 2026

Next Ex Dividend date

24 sie 2026

Market Stats

By TradingEconomics

Market Cap

2.7B

11B

Previous open

72.12

Previous close

72.4

News Sentiment

By Acuity

59%

41%

291 / 340 Ranking in Healthcare

Bio-Techne Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 sie 2026, 19:16 UTC

Correlated Moves
News

Bio-Techne Corp corrected its dividend record date to August 24, 2026. Shares are trading roughly flat amid broader market dynamics.

5 sie 2026, 19:16 UTC

Correlated Moves

Bio-Techne Corp's shares are lower today, reflecting declines in the Russell 2000 Index. The stock remains near the upper end of its one-month trading range.

4 sie 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are higher in after-market trading, buoyed by positive sentiment from U.S.-Iran negotiations and gains in major technology stocks.

3 sie 2026, 19:26 UTC

Correlated Moves

Bio-Techne Corp is advancing, reflecting broader market positivity amid gains in major tech stocks and falling energy prices. The stock is near its one-month trading range high.

31 lip 2026, 22:02 UTC

Correlated Moves

Bio-Techne Corp shares are lower in after-market trading amid a broader market downturn, reflecting negative sentiment impacting price action.

30 lip 2026, 18:26 UTC

Correlated Moves

Bio-Techne Corp is trading roughly flat as the broader market recovers from declines, influenced by rising Treasury yields and inflation concerns.

29 lip 2026, 22:03 UTC

Bio-Techne Corp shares are lower in after-market hours, reflecting a decline since Wednesday's close amid cautious market sentiment and geopolitical tensions.

20 lip 2026, 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Peer Comparison

Price change

Bio-Techne Corp Forecast

Price Target

By TipRanks

-1.86% downside

12 Months Forecast

Average 70.89 USD  -1.86%

High 73 USD

Low 62 USD

Based on 11 Wall Street analysts offering 12 month price targets forBio-Techne Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

11 ratings

1

Buy

10

Hold

0

Sell

Sentiment

By Acuity

291 / 340 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat